Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H (8329) AI Stock Analysis

• Market Cap: HK$290.29M
• Dividend Yield: 3.1%
• Average Volume (3M): 483.00K
• Price to Earnings (P/E): 10.7
• Beta (1Y): 0.16
• Revenue Growth: -4.17%
• EPS Growth: -1.83%
• Country: HK
• Employees: 1,485
• Sector: Healthcare
• Sector Strength: 39
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.02
• Shares Outstanding: 426,000,000
• 10 Day Avg. Volume: 630,000
• 30 Day Avg. Volume: 483,000
• PEG Ratio: 0.08
• Price to Book (P/B): 0.31
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 60 Neutral
• Price Target: HK$0.00 ▼(-100.00%Downside)

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. faces financial and operational challenges, with declining revenue and cash flow issues being significant concerns. Technical indicators suggest weak market momentum, but the stock's valuation appears reasonable, providing a potential opportunity if operational improvements can be realized.

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H Business Overview & Revenue Model

Company Description

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H (8329) is a biotechnology company based in Shenzhen, China, primarily focused on the research, development, manufacturing, and distribution of biopharmaceutical products. The company operates within the healthcare and pharmaceutical sectors and offers a range of products including vaccines, therapeutic biological products, and diagnostic reagents. With a strong emphasis on innovation, Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. aims to contribute to public health by providing high-quality medical solutions.

How the Company Makes Money

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. generates revenue primarily through the sale of its biopharmaceutical products. The company's key revenue streams include the production and distribution of vaccines, which are sold to healthcare providers and government agencies, and therapeutic biological products, which are sold to hospitals and medical institutions. Additionally, the company may engage in strategic partnerships and collaborations with other pharmaceutical companies to enhance its product offerings and expand its market reach. Revenue is also generated from diagnostic reagents used in medical testing and research, contributing to the company’s overall financial performance.

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H Financial Statement Overview

Summary

The company shows strong balance sheet metrics with a high equity ratio and low debt-to-equity ratio, indicating financial stability. However, declining revenues, margins, and concerning cash flow metrics reflect operational challenges and liquidity risks.

Income Statement

The company experienced a decline in revenue from 2023 to 2024, indicating a potential challenge in maintaining sales momentum. Gross profit margin decreased from 41.3% in 2023 to 31.5% in 2024, suggesting increased cost pressures or pricing challenges. Net profit margin slightly improved to 2.4% in 2024 from 2.3% in 2023, reflecting some operational efficiencies. EBIT and EBITDA margins also show a decline, emphasizing operational headwinds.

Balance Sheet

The company maintains a strong equity base with an equity ratio of 66.7% in 2024, indicating good financial stability. The debt-to-equity ratio remains low at 0.11, suggesting conservative leverage practices. However, slight declines in total assets and stockholders' equity could pose future challenges if not addressed.

Cash Flow

Cash flow metrics are concerning, with operating cash flow dropping to zero in 2024, potentially impacting liquidity. With free cash flow also at zero, the company may face challenges in funding new investments or expansions without additional financing.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.04B	1.06B	986.69M	838.80M	1.03B
Gross Profit	328.04M	439.24M	444.14M	374.10M	574.36M
EBITDA	62.87M	69.89M	125.24M	73.97M	76.74M
Net Income	25.01M	24.13M	54.35M	35.96M	36.59M
Balance Sheet
Total Assets	1.40B	1.42B	1.45B	1.31B	1.12B
Cash, Cash Equivalents and Short-Term Investments	283.42M	382.21M	350.10M	311.14M	415.88M
Total Debt	105.43M	89.69M	92.69M	105.69M	10.06M
Total Liabilities	371.99M	399.46M	442.93M	363.17M	225.21M
Stockholders Equity	933.18M	908.17M	884.04M	829.70M	793.74M
Cash Flow
Free Cash Flow	2.20M	38.32M	41.51M	-85.00M	55.69M
Operating Cash Flow	24.41M	53.69M	61.22M	-69.92M	93.64M
Investing Cash Flow	-114.62M	60.90M	10.76M	-181.57M	-30.68M
Financing Cash Flow	1.43M	-32.48M	-9.02M	66.75M	-35.28M

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.18
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8329, the sentiment is Neutral. The current price of 0.18 is below the 20-day moving average (MA) of 0.19, above the 50-day MA of 0.18, and above the 200-day MA of 0.11, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 41.17 is Neutral, neither overbought nor oversold. The STOCH value of 30.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:8329.

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
8329	60 Neutral	HK$290.29M	10.68	2.72%	3.10%	-4.17%	-1.83%
Sector *	60 Neutral	HK$15.58B	5.65	-7.43%	4.32%	11.60%	-21.06%
0897	55 Neutral	HK$343.16M	48.41	0.55%	9.84%	-66.75%	-83.83%
8622	52 Neutral	HK$197.69M	―	-7.93%	―	1.13%	38.41%
1652	49 Neutral	HK$279.38M	―	-40.39%	―	-43.73%	-434.56%
1011	48 Neutral	HK$310.15M	―		―	―	―